

PENETRATION OF THE JAPANESE MARKET IS EXTREMELY FAST – ALREADY 100 SYSTEMS INSTALLED.

FUJIFILM RI Pharma Co. Ltd own the exclusive rights to the Japanese version of EXINI Bone™ and only four months after the agreement was signed, already 100 systems has been installed at various clinics throughout Japan. These will be followed by several publications confirming the quality and productivity improvement of the product.

The customized version of EXINI Bone™, referred to as "Bonenavi" in the Japanese market, has been very successful. The extensive installation rate will now also been followed by several publications which will confirm the quality and productivity improvement for bone scan images which both patients and clinicians

- "I'm very proud of my organization which have made this fast penetration possible." says Morita Toshiya, General Manager Marketing, FUJIFILM RI Pharma Co. Ltd., and continues: *"The potential of Bonenavi including the unique BSI value (bone scan index) for prediction of bone metastasis progression is very good."*
- Magnus Aurell, CEO EXINI Diagnostics AB, comments: *"The speed of installations is impressive and faster than expected. I'm very glad that the Japanese doctors have realized the potential of our concept. This fast penetration will also be a good test on our quality of the product and also our level of support and service capacity. Added to this the reputation of Bonenavi will give us an interesting dialogue regarding our other products."*

For more information, please contact:

Magnus Aurell, CEO

Phone: 046-286 54 25

E-mail: magnus.aurell @ exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make their own interpretation of radiology images and providing diagnostic suggestions. In this way the system is used as a decision support for diagnosing sparkling doctor. EXINI working on products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. Founded in 1999 by Professor Lars Edenbrandt and currently has 13 employees. EXINI is listed on the stock market square and has about 400 shareholders. Principal owner, Bo Håkansson.